|
| 
|
 |
|
|
|
 |
|
|
 |
|
 |
 |
|
|
A
STRONG MEDICAL & SCIENTIFIC FOUNDATION
|
|
|
|
|
Guided by a world-renowned Scientific Advisory Board,
InterCure, the maker of RESPERATE, is committed
to evidence-based medicine, clinical validation
and a sound scientific foundation.
The Company has already demonstrated strong clinical
validation for Resperate. Clinical achievements
for Resperate, our non-drug medical device for
lowering blood pressure, include:
|
|
|
 |
The
first and only medical device
indicated for the
adjunctive treatment of hypertension. |
 |
|
|
|
|
|
|
14/9
mmHg average sustained blood pressure reductions
within 8 weeks.
No side effects, no drug interactions.
Results of six clinical trials were published
in peer-reviewed medical journals.
[references 1-5]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INFORMATIVE
DOCUMENTS |
|
For
your convenience we made the documents below
available as PDF.
(PDF requires Acrobat Reader software. If
you don't have Acrobat Reader, please press
here
for a free download)
|
|
Clinical
Information Brochure |
 |
272
KB |
 |
|
Patient
Education Brochure |
|
313 KB |
|
|
|
|
|
|
|
|
REFERENCES |
|
|
Schein
M, Gavish B, Herz M et al. "Treating
hypertension with a device that slows and
regularizes breathing: a randomized double-blind
controlled study." J Human Hyperten 2001;
15(4): 271 - 278.
Grossman E, Grossman A, Schein MH, Zimlichman
R, Gavish B "Breathing-control lowers
blood pressure." J Human Hyperten 2001;
15(4): 263 - 269.
Rosenthal T, Alter A, Peleg E, Gavish B. "Device-guided
breathing exercises reduce blood pressure
and ambulatory and home measurement."
Am J Hyperten 2001; 14(1): 74 - 76.
Giannattasio C, Failla M, Meles E, Gentile
G, Grappiolo A and Mancia G “Efficacy
of self treatment of hypertension at home
with device-guided breathing.” Am J
Hyperten 2002; 15(4,2)186A.
Elliott W, Izzo J, Rosing D, Snyder C, White
W, Alter A, Gavish B, and Black B “Hypertension
reduction by device-guided breathing shows
a dose-response relationship.” Am J
Hyperten 2002; 15(4,2)186A.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
